Triple negative breast cancer.
Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. This mini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients.
Department of Radiobiology, Faculty of Science, Istanbul University, Istanbul, Turkey E-mail : idil.cetin@istanbul.edu.tr.
Idil
I
Cetin
Mehmet
M
Topcul
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D011379:Prognosis; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D000970:Antineoplastic Agents